Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Mesa Laboratories (MLAB) over the last 13 years, with Q4 2025 value amounting to $14.6 million.

  • Mesa Laboratories' Current Deferred Revenue fell 95.85% to $14.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.6 million, marking a year-over-year decrease of 95.85%. This contributed to the annual value of $14.8 million for FY2025, which is 562.92% down from last year.
  • Per Mesa Laboratories' latest filing, its Current Deferred Revenue stood at $14.6 million for Q4 2025, which was down 95.85% from $14.3 million recorded in Q3 2025.
  • Over the past 5 years, Mesa Laboratories' Current Deferred Revenue peaked at $16.3 million during Q3 2022, and registered a low of $9.0 million during Q1 2021.
  • Over the past 5 years, Mesa Laboratories' median Current Deferred Revenue value was $14.7 million (recorded in 2023), while the average stood at $14.3 million.
  • In the last 5 years, Mesa Laboratories' Current Deferred Revenue skyrocketed by 7110.29% in 2021 and then crashed by 1003.93% in 2023.
  • Mesa Laboratories' Current Deferred Revenue (Quarter) stood at $13.8 million in 2021, then grew by 17.56% to $16.2 million in 2022, then fell by 9.33% to $14.7 million in 2023, then dropped by 0.05% to $14.7 million in 2024, then dropped by 0.96% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q4 2025, $14.3 million for Q3 2025, and $15.1 million during Q2 2025.